Revance Therapeutics, Inc. - Common Stock (RVNC)

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Crown Laboratories will acquire Revance Therapeutics for $924 million, paying $6.66 per share — a premium of 89%.

Revance Therapeutics stock is up on Monday as RVNC investors celebrate a $924 million merger agreement with Crown Laboratories.

RVNC stock results show that Revance Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

The big pharma company's top drug is losing ground, but its dividend keeps rising.

Although breakout stocks present high risks, the underlying lack of predictability provides fuel for tremendous upside.

Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.

10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.

RVNC stock results show that Revance Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session.

U.S. stock futures were lower this morning, with the Dow futures falling by around 100 points on Monday. Shares of GDS Holdings Limited (NASDAQ: GDS) shares rose sharply in today’s pre-market trading.

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.